Eaton Vance Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $74.9M | Buy |
906,031
+3,287
| +0.4% | +$316K | 0.11% | 189 |
|
|
2022
Q2 | $85.8M | Buy |
902,744
+425,326
| +89% | +$44M | 0.12% | 176 |
|
|
2022
Q1 | $56.2M | Buy |
477,418
+131,712
| +38% | +$14.8M | 0.06% | 289 |
|
|
2021
Q4 | $44.8M | Buy |
+345,706
| New | +$40.3M | 0.05% | 321 |
|
|
2021
Q3 | – | Sell |
-396,484
| Closed | -$41.1M | – | 2214 |
|
|
2021
Q2 | $41.1M | Buy |
396,484
+32,045
| +9% | +$3.02M | 0.06% | 317 |
|
|
2021
Q1 | $30.5M | Buy |
364,439
+33,615
| +10% | +$2.84M | 0.05% | 353 |
|
|
2020
Q4 | $30.2M | Sell |
330,824
-54,649
| -14% | -$4.53M | 0.05% | 345 |
|
|
2020
Q3 | $30.8M | Buy |
385,473
+21,615
| +6% | +$1.69M | 0.06% | 289 |
|
|
2020
Q2 | $25.1M | Buy |
363,858
+195
| +0.1% | +$13.9K | 0.05% | 300 |
|
|
2020
Q1 | $22.9M | Buy |
363,663
+52,494
| +17% | +$3.79M | 0.06% | 280 |
|
|
2019
Q4 | $24.2M | Sell |
311,169
-91,716
| -23% | -$7.16M | 0.05% | 302 |
|
|
2019
Q3 | $29.5M | Buy |
402,885
+819
| +0.2% | +$57.5K | 0.06% | 249 |
|
|
2019
Q2 | $24.8M | Buy |
+402,066
| New | +$24.3M | 0.05% | 272 |
|
|
2018
Q4 | – | Sell |
-417,885
| Closed | -$24.3M | – | 1186 |
|
|
2018
Q3 | $24.3M | Sell |
417,885
-53,193
| -11% | -$2.6M | 0.05% | 258 |
|
|
2018
Q2 | $22.9M | Sell |
471,078
-72,609
| -13% | -$3.39M | 0.05% | 261 |
|
|
2018
Q1 | $25.3M | Sell |
543,687
-79,302
| -13% | -$3.44M | 0.03% | 350 |
|
|
2017
Q4 | $23.4M | Sell |
622,989
-51,807
| -8% | -$1.9M | 0.06% | 258 |
|
|
2017
Q3 | $24.6M | Sell |
674,796
-222,648
| -25% | -$8.49M | 0.06% | 239 |
|
|
2017
Q2 | $35.4M | Sell |
897,444
-735,558
| -45% | -$26.8M | 0.09% | 196 |
|
|
2017
Q1 | $51.2M | Buy |
1,633,002
+719,583
| +79% | +$22.5M | 0.14% | 155 |
|
|
2016
Q4 | $28.5M | Buy |
913,419
+167,718
| +22% | +$5.43M | 0.08% | 197 |
|
|
2016
Q3 | $30M | Buy |
745,701
+112,371
| +18% | +$4.23M | 0.09% | 183 |
|
|
2016
Q2 | $21.1M | Buy |
633,330
+533,952
| +537% | +$18.3M | 0.06% | 213 |
|
|
2016
Q1 | $2.92M | Hold |
99,378
| – | – | 0.01% | 483 |
|
|
2015
Q4 | $2.62M | Hold |
99,378
| – | – | 0.01% | 506 |
|
|
2015
Q3 | $2.35M | Buy |
99,378
+66,378
| +201% | +$1.6M | 0.01% | 520 |
|
|
2015
Q2 | $783K | Hold |
33,000
| – | – | ﹤0.01% | 669 |
|
|
2015
Q1 | $784K | Hold |
33,000
| – | – | ﹤0.01% | 722 |
|
|
2014
Q4 | $701K | Hold |
33,000
| – | – | ﹤0.01% | 719 |
|
|
2014
Q3 | $562K | Hold |
33,000
| – | – | ﹤0.01% | 735 |
|
|
2014
Q2 | $473K | Buy |
+33,000
| New | +$447K | ﹤0.01% | 764 |
|
Other funds holding EW
Eaton Vance Management's EW Position: Q3 2022 in Review
Eaton Vance Management increased its Edwards Lifesciences (EW) stake by 0.36% in Q3 2022, buying an estimated $316K and bringing the position to 906,031 shares worth $74.9M. The position accounts for 0.11% of the portfolio, ranked #189.
Eaton Vance Management first reported a position in EW in Q2 2014 and has held it in 31 quarters since. The position peaked at $85.8M in Q2 2022. 1,246 funds tracked by Wall St. Rank hold EW as of Q3 2022.
- Eaton Vance Management held 906,031 shares of Edwards Lifesciences worth $74.9M as of Q3 2022.
- Eaton Vance Management bought 3,287 Edwards Lifesciences shares in Q3 2022, an estimated $316K.
- Edwards Lifesciences made up 0.11% of Eaton Vance Management's portfolio in Q3 2022, its #189 holding.
- Eaton Vance Management first reported a position in Edwards Lifesciences in Q2 2014 and has held it in 31 quarters since.
- Eaton Vance Management's Edwards Lifesciences position peaked at $85.8M in Q2 2022.
- 1,246 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2022.
Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.